Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy
Introduction and Purpose: Crohn’s disease (CD) is a chronic inflammatory condition with an unpredictable course. Despite the availability of biologics, many patients fail to achieve sustained remission. Risankizumab, an anti-IL-23 p19 monoclonal antibody, offers a new therapeutic option. This stu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-05-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/59986 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850190926915305472 |
|---|---|
| author | Monika Babczyńska Agnieszka Buliszak Piotr Marcjasz Anna Bioły Agnieszka Borończyk Piotr Zając |
| author_facet | Monika Babczyńska Agnieszka Buliszak Piotr Marcjasz Anna Bioły Agnieszka Borończyk Piotr Zając |
| author_sort | Monika Babczyńska |
| collection | DOAJ |
| description |
Introduction and Purpose:
Crohn’s disease (CD) is a chronic inflammatory condition with an unpredictable course. Despite the availability of biologics, many patients fail to achieve sustained remission. Risankizumab, an anti-IL-23 p19 monoclonal antibody, offers a new therapeutic option. This study compares risankizumab with other biologics (infliximab, adalimumab, ustekinumab, vedolizumab), focusing on long-term outcomes and quality of life.
Materials and Methods:
This review analyzes data from phase III trials (ADVANCE, MOTIVATE, FORTIFY), the SEQUENCE head-to-head trial with ustekinumab, and observational studies. Outcomes assessed include clinical remission, endoscopic response, safety, and health-related quality of life (IBDQ, SF-36, FACIT-F).
Brief Description of the State of Knowledge:
Biologics targeting TNF-α, integrins, or IL-12/23 are effective but limited by non-response or loss of response. Risankizumab selectively inhibits IL-23, sparing the IL-12/Th1 pathway. It has demonstrated higher remission and mucosal healing rates than placebo and maintains efficacy in patients previously exposed to multiple biologics.
Conclusions:
Risankizumab is a safe and effective option in moderate-to-severe CD, especially after failure of other biologics. It improves both clinical and endoscopic outcomes, as well as patient quality of life. Further direct comparisons are warranted to clarify its role in treatment algorithms.
|
| format | Article |
| id | doaj-art-11fb1196864a461a9ccc3b8d92d70daf |
| institution | OA Journals |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-11fb1196864a461a9ccc3b8d92d70daf2025-08-20T02:15:06ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-05-014110.12775/QS.2025.41.59986Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior TherapyMonika Babczyńska0https://orcid.org/0009-0007-8430-5838Agnieszka Buliszak1https://orcid.org/0009-0002-2434-4775Piotr Marcjasz2https://orcid.org/0009-0007-8247-5200Anna Bioły3https://orcid.org/0009-0005-2246-3537Agnieszka Borończyk4https://orcid.org/0009-0001-3866-9370Piotr Zając5https://orcid.org/0009-0004-1516-8487Medical University of Silesia, Ul. Poniatowskiego 15, 40-055 Katowice, PolandMedical University of Silesia, Ul. Poniatowskiego 15, 40-055 Katowice, PolandMedical University of Silesia, Ul. Poniatowskiego 15, 40-055 Katowice, Poland Medical University of Silesia, Ul. Poniatowskiego 15, 40-055 Katowice, Poland Medical University of Silesia, Ul. Poniatowskiego 15, 40-055 Katowice, PolandUpper Silesian Medical Center of Prof. Leszek Giec of the Silesian Medical University, Ziołowa 45-47, 40-635 Katowice – Ochojec Introduction and Purpose: Crohn’s disease (CD) is a chronic inflammatory condition with an unpredictable course. Despite the availability of biologics, many patients fail to achieve sustained remission. Risankizumab, an anti-IL-23 p19 monoclonal antibody, offers a new therapeutic option. This study compares risankizumab with other biologics (infliximab, adalimumab, ustekinumab, vedolizumab), focusing on long-term outcomes and quality of life. Materials and Methods: This review analyzes data from phase III trials (ADVANCE, MOTIVATE, FORTIFY), the SEQUENCE head-to-head trial with ustekinumab, and observational studies. Outcomes assessed include clinical remission, endoscopic response, safety, and health-related quality of life (IBDQ, SF-36, FACIT-F). Brief Description of the State of Knowledge: Biologics targeting TNF-α, integrins, or IL-12/23 are effective but limited by non-response or loss of response. Risankizumab selectively inhibits IL-23, sparing the IL-12/Th1 pathway. It has demonstrated higher remission and mucosal healing rates than placebo and maintains efficacy in patients previously exposed to multiple biologics. Conclusions: Risankizumab is a safe and effective option in moderate-to-severe CD, especially after failure of other biologics. It improves both clinical and endoscopic outcomes, as well as patient quality of life. Further direct comparisons are warranted to clarify its role in treatment algorithms. https://apcz.umk.pl/QS/article/view/59986Crohn's diseaserisankizumabbiologic therapiesustekinumabquality of lifeclinical remission |
| spellingShingle | Monika Babczyńska Agnieszka Buliszak Piotr Marcjasz Anna Bioły Agnieszka Borończyk Piotr Zając Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy Quality in Sport Crohn's disease risankizumab biologic therapies ustekinumab quality of life clinical remission |
| title | Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy |
| title_full | Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy |
| title_fullStr | Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy |
| title_full_unstemmed | Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy |
| title_short | Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy |
| title_sort | comparative effectiveness of risankizumab vs other biologics in crohn s disease long term and quality of life outcomes after inadequate response to prior therapy |
| topic | Crohn's disease risankizumab biologic therapies ustekinumab quality of life clinical remission |
| url | https://apcz.umk.pl/QS/article/view/59986 |
| work_keys_str_mv | AT monikababczynska comparativeeffectivenessofrisankizumabvsotherbiologicsincrohnsdiseaselongtermandqualityoflifeoutcomesafterinadequateresponsetopriortherapy AT agnieszkabuliszak comparativeeffectivenessofrisankizumabvsotherbiologicsincrohnsdiseaselongtermandqualityoflifeoutcomesafterinadequateresponsetopriortherapy AT piotrmarcjasz comparativeeffectivenessofrisankizumabvsotherbiologicsincrohnsdiseaselongtermandqualityoflifeoutcomesafterinadequateresponsetopriortherapy AT annabioły comparativeeffectivenessofrisankizumabvsotherbiologicsincrohnsdiseaselongtermandqualityoflifeoutcomesafterinadequateresponsetopriortherapy AT agnieszkaboronczyk comparativeeffectivenessofrisankizumabvsotherbiologicsincrohnsdiseaselongtermandqualityoflifeoutcomesafterinadequateresponsetopriortherapy AT piotrzajac comparativeeffectivenessofrisankizumabvsotherbiologicsincrohnsdiseaselongtermandqualityoflifeoutcomesafterinadequateresponsetopriortherapy |